1.Agarwal A, Aggarwal K, Gupta V: Management of neovascular age-related macular degeneration: A review on landmark randomized controlled trials. Middle East Afr J Ophthalmol 2016, 23(1):27–37.
2.Ferreira A, Sagkriotis A, Olson M, Lu J, Makin C, Milnes F: Treatment frequency and dosing interval of ranibizumab and aflibercept for neovascular age-related macular degeneration in routine clinical practice in the USA. PLoS One 2015, 10(7):e0133968.
3.Ferrara N, Damico L, Shams N, Lowman H, Kim R: Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. Retina 2006, 26(8):859–870.
4.LUCENTIS™ (ranibizumab injection) prescribing information [www.accessdata.fda.gov/drugsatfda_docs/label/2014/125156s105lbl.pdf]
5.Summary of product characteristics. Lucentis 10 mg/ml solution for injection [Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000715/WC500043546.pdf]
6.Busbee BG, Ho AC, Brown DM, Heier JS, Suner IJ, Li Z, Rubio RG, Lai P, Harbor Study Group: Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2013, 120(5):1046–1056.
7.Comparison of Age-related Macular Degeneration Treatments Trials Research Group, Martin DF, Maguire MG, Fine SL, Ying GS, Jaffe GJ, Grunwald JE, Toth C, Redford M, Ferris FL, 3rd: Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results. Ophthalmology 2012, 119(7):1388–1398.
8.Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW, Jr., Esquiabro M: An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007, 143(4):566–583.
9.Comparison of Age-related Macular Degeneration Treatments Trials Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011, 364(20):1897–1908.
10.Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W, Davis JL, Flynn HW, Jr., Esquiabro M: A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009, 148(1):43–58 e41.
11.Waldstein SM, Wright J, Warburton J, Margaron P, Simader C, Schmidt-Erfurth U: Predictive Value of Retinal Morphology for Visual Acuity Outcomes of Different Ranibizumab Treatment Regimens for Neovascular AMD. Ophthalmology 2016, 123(1):60–69.
12.Efficacy and safety of two treatment regimens of 0.5 mg ranibizumab intravitreal injections guided by functional and/or anatomical criteria, in patients with neovascular age-related macular degeneration (OCTAVE) [Available at:https://clinicaltrials.gov/ct2/show/NCT01780935]
13.Schmidt-Erfurth U, Chong V, Loewenstein A, Larsen M, Souied E, Schlingemann R, Eldem B, Mones J, Richard G, Bandello F et al: Guidelines for the management of neovascular age-related macular degeneration by the European Society of Retina Specialists (EURETINA). Br J Ophthalmol 2014, 98(9):1144–1167.
14.Group. RCoOAG: Age-related macular degeneration: guidelines for management. ; 2013.
15.Ritter M, Elledge J, Simader C, Deak GG, Benesch T, Blodi BA, Schmidt-Erfurth UM: Evaluation of optical coherence tomography findings in age-related macular degeneration: a reproducibility study of two independent reading centres. Br J Ophthalmol 2011, 95(3):381–385.
16.Schmucker CM, Rucker G, Sommer H, Virgili G, Loke YK, Oeller P, Agostini H, Ehlken C: Treatment as Required versus Regular Monthly Treatment in the Management of Neovascular Age-Related Macular Degeneration: A Systematic Review and Meta-Analysis. PLoS One 2015, 10(9):e0137866.
17.Patel PJ, Browning AC, Chen FK, Da Cruz L, Tufail A: Interobserver agreement for the detection of optical coherence tomography features of neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci 2009, 50(11):5405–5410.
18.Castillo MM, Mowatt G, Elders A, Lois N, Fraser C, Hernandez R, Amoaku W, Burr JM, Lotery A, Ramsay CR et al: Optical coherence tomography for the monitoring of neovascular age-related macular degeneration: a systematic review. Ophthalmology 2015, 122(2):399–406.
19.Ho AC, Busbee BG, Regillo CD, Wieland MR, Van Everen SA, Li Z, Rubio RG, Lai P, Harbor Study Group: Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration. Ophthalmology 2014, 121(11):2181–2192.
20.Ivan Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, Reeves BC: Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012, 119(7):1399–1411.
21.Kodjikian L, Souied EH, Mimoun G, Mauget-Faysse M, Behar-Cohen F, Decullier E, Huot L, Aulagner G, Gefal Study Group: Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: Results from the GEFAL noninferiority randomized trial. Ophthalmology 2013, 120(11):2300–2309.
22.Cohen SY, Mimoun G, Oubraham H, Zourdani A, Malbrel C, Quere S, Schneider V, Lumiere Study Group: Changes in visual acuity in patients with wet age-related macular degeneration treated with intravitreal ranibizumab in daily clinical practice: the LUMIERE study. Retina 2013, 33(3):474–481.
23.Finger RP, Wiedemann P, Blumhagen F, Pohl K, Holz FG: Treatment patterns, visual acuity and quality-of-life outcomes of the WAVE study - a noninterventional study of ranibizumab treatment for neovascular age-related macular degeneration in Germany. Acta Ophthalmol 2013, 91(6):540–546.
24.Holz FG, Tadayoni R, Beatty S, Berger A, Cereda MG, Cortez R, Hoyng CB, Hykin P, Staurenghi G, Heldner S et al: Multi-country real-life experience of anti-vascular endothelial growth factor therapy for wet age-related macular degeneration. Br J Ophthalmol 2015, 99(2):220–226.
25.Pagliarini S, Beatty S, Lipkova B, Perez-Salvador Garcia E, Reynders S, Gekkieva M, Si Bouazza A, Pilz S: A 2-Year, Phase IV, Multicentre, Observational Study of Ranibizumab 0.5 mg in Patients with Neovascular Age-Related Macular Degeneration in Routine Clinical Practice: The EPICOHORT Study. J Ophthalmol 2014, 2014:857148.
26.Rakic JM, Leys A, Brie H, Denhaerynck K, Pacheco C, Vancayzeele S, Hermans C, Macdonald K, Abraham I: Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: the HELIOS study. Clin Ophthalmol 2013, 7:1849–1858.
27.Simader C, Ritter M, Bolz M, Deak GG, Mayr-Sponer U, Golbaz I, Kundi M, Schmidt-Erfurth UM: Morphologic parameters relevant for visual outcome during anti-angiogenic therapy of neovascular age-related macular degeneration. Ophthalmology 2014, 121(6):1237–1245.
28.Mrejen S, Jung JJ, Chen C, Patel SN, Gallego-Pinazo R, Yannuzzi N, Xu L, Marsiglia M, Boddu S, Freund KB: Long-Term Visual Outcomes for a Treat and Extend Anti-Vascular Endothelial Growth Factor Regimen in Eyes with Neovascular Age-Related Macular Degeneration. J Clin Med 2015, 4(7):1380–1402.
29.Ritter M, Simader C, Bolz M, Deak GG, Mayr-Sponer U, Sayegh R, Kundi M, Schmidt-Erfurth UM: Intraretinal cysts are the most relevant prognostic biomarker in neovascular age-related macular degeneration independent of the therapeutic strategy. Br J Ophthalmol 2014, 98(12):1629–1635.